GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

ClinicalTrials.gov ID: NCT04864054

Public ClinicalTrials.gov record NCT04864054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.

Study identification

NCT ID: NCT04864054
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Eureka Therapeutics Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Interventions

ECT204 T cells Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 11, 2022 (Actual)
Primary completion: Dec 31, 2027 (Estimated)
Completion: Dec 31, 2027 (Estimated)
Last update posted: Sep 10, 2026

2022 – 2027

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Kansas University Medical Center, Principal Investigator:	Westwood	Kansas	66205	Completed
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14263	Completed
Montefiore Einstein Comprehensive Cancer Center	The Bronx	New York	10467	Recruiting
Oregon Health and Sciences University	Portland	Oregon	97239	Recruiting
University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center	Dallas	Texas	75235	Recruiting
Fred Hutchinson Cancer Center, University of Washington	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04864054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 10, 2026 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04864054 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →